Evidence map›Paper›PMID 38343053›Full record

ReviewMini reviews in medicinal chemistry2024

Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.

Ekta Shirbhate, Vaibhav Singh, Aditya Mishra, Varsha Jahoriya, Ravichandran Veerasamy, Amit K Tiwari, Harish Rajak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Ekta ShirbhateDepartment of Pharmacy, Guru Ghasidas University, Bilaspur-495 009, (C.G.), India.ORCID 0000-0001-8190-8106
Vaibhav SinghDepartment of Pharmacy, Guru Ghasidas University, Bilaspur-495 009, (C.G.), India.
Aditya MishraDepartment of Pharmacy, Guru Ghasidas University, Bilaspur-495 009, (C.G.), India.
Varsha JahoriyaDepartment of Pharmacy, Guru Ghasidas University, Bilaspur-495 009, (C.G.), India.
Ravichandran VeerasamyFaculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia.ORCID 0000-0001-9903-8890
Amit K TiwariUAMS College of Pharmacy; UAMS - University of Arkansas for Medical Sciences, (AR) USA.ORCID 0000-0002-0275-0724
Harish RajakDepartment of Pharmacy, Guru Ghasidas University, Bilaspur-495 009, (C.G.), India.ORCID 0000-0003-2008-2827
Guru Ghasidas Vishwavidyalaya · INAIMST University · MYUniversity of Arkansas for Medical Sciences · US

Funding

Department of Science and Technology (DST), New Delhi IF210097Indian Council of Medical Research, ICMR, New Delhi 58/33/2020/PHA/BMS
6 · The paper itself

Abstract

Chemotherapy is still the major method of treatment for many types of cancer. Curative cancer therapy is hampered significantly by medication resistance. Acidic organelles like lysosomes serve as protagonists in cellular digestion. Lysosomes, however, are gaining popularity due to their speeding involvement in cancer progression and resistance. For instance, weak chemotherapeutic drugs of basic nature permeate through the lysosomal membrane and are retained in lysosomes in their cationic state, while extracellular release of lysosomal enzymes induces cancer, cytosolic escape of lysosomal hydrolases causes apoptosis, and so on. Drug availability at the sites of action is decreased due to lysosomal drug sequestration, which also enhances cancer resistance. This review looks at lysosomal drug sequestration mechanisms and how they affect cancer treatment resistance. Using lysosomes as subcellular targets to combat drug resistance and reverse drug sequestration is another method for overcoming drug resistance that is covered in this article. The present review has identified lysosomal drug sequestration as one of the reasons behind chemoresistance. The article delves deeper into specific aspects of lysosomal sequestration, providing nuanced insights, critical evaluations, or novel interpretations of different approaches that target lysosomes to defect cancer.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmLysosomesNeoplasmsAnimalsHumansAntineoplastic AgentsChemotherapeuticsexocytosislysosomal sequestrationlysosomelysosomotropic agents.multidrug resistance

Identifiers

PMID38343053
OpenAlexW4391749876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.